HepaVue Dx SRL
1.0 FTEHepaVue Dx reported total assets of €3.71m at the end of the 2025 financial year (annual accounts filed with the NBB on 26 Aug 2026), with 1 full-time equivalent.
The score of HepaVue Dx shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Accounts of the company itself (not consolidated).
The full file covers 2 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
HepaVue Dx's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 26 Aug 2026
- Year ended 31 Dec 2024filed on 28 Aug 2025
HepaVue Dx's financial analysis
- Solvency11.6%sector median: 58.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of HepaVue Dx
HepaVue Dx's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0803.100.414
- VAT number
- BE0803100414
- Peppol
- Registered · 0208:0803100414 · as of 12 Nov 2026
- Legal form
- SRL
- Incorporated
- 23 Jun 2023
- Registered office
- 1410 Waterloo
- Size
- Micro · 1.0 FTE
- Latest accounts
- 2025 · filed on 26 Aug 2026
- Activity
- Research and experimental development on biotechnology (NACE 72101)
HepaVue Dx (SRL) has been based in Waterloo since 2023, active in: research and experimental development on biotechnology. For 2025, it reports a net loss of 351,134 € and equity of 429,994 €; its revenue is not published. With 1.0 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 11.6%, below the median of its sector (58.2%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to HepaVue Dx
Companies in the same business, of comparable size and area, outside its group.
- NanoBiotech Research and experimental development on natural sciences and engineering Diepenbeek · balance sheet 1,834 €
- Envitec Measurements and Analytics SA Research and experimental development on natural sciences and engineering Gembloux · balance sheet €3.64m
- K5 Therapeutics Research and experimental development on natural sciences and engineering Leuven · balance sheet €3.56m
- ImmuneSpec Research and experimental development on natural sciences and engineering Niel · balance sheet €3.54m
- Dr. J. Bellon Research and experimental development on natural sciences and engineering Buggenhout · balance sheet €3.14m
- Elmace Research and experimental development on natural sciences and engineering Aalter · balance sheet €3.11m
- CM4Cure Research and experimental development on natural sciences and engineering Liège · balance sheet €4.57m
- Pacira Belgium Research and experimental development on natural sciences and engineering Eupen · balance sheet €3.00m
Frequently asked questions about HepaVue Dx
What is the revenue of HepaVue Dx?
HepaVue Dx files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of HepaVue Dx?
In Belgium, the VAT number is the company number prefixed with BE: BE0803100414 for HepaVue Dx, if the company is VAT-registered. Its company number (CBE) is 0803.100.414.
Where is the registered office of HepaVue Dx?
According to the CBE register, the registered office of HepaVue Dx is in 1410 Waterloo.
What is the equity of HepaVue Dx?
At the close of the 2025 financial year, the equity of HepaVue Dx amounts to 429,994 €, a solvency of 11.6% of total assets.
How many people work at HepaVue Dx?
1.0 full-time equivalents on average according to the 2025 social balance sheet.
Who manages HepaVue Dx?
The register lists 2 active mandates at HepaVue Dx. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of HepaVue Dx
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →